309 related articles for article (PubMed ID: 31054583)
1. A nomogram for predicting the HER2 status in female patients with breast cancer in China: a nationwide, multicenter, 10-year epidemiological study.
Zhang H; Xie P; Li Z; Huang R; Feng W; Kong Y; Xu F; Zhao L; Song Q; Li J; Zhang B; Fan J; Qiao Y; Xie X; Zheng S; He J; Wang K
Diagn Pathol; 2019 May; 14(1):35. PubMed ID: 31054583
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of a Nomogram for Individually Predicting Pathologic Complete Remission After Preoperative Chemotherapy in Chinese Breast Cancer: A Population-Based Study.
Hou N; Xiao J; Wang Z; Wu Y; Hou G; Guo L; Zhang J; Ling R
Clin Breast Cancer; 2020 Dec; 20(6):e682-e694. PubMed ID: 32713825
[TBL] [Abstract][Full Text] [Related]
3. A Nomogram for Predicting the Pathological Response of Axillary Lymph Node Metastasis in Breast Cancer Patients.
Jin X; Jiang YZ; Chen S; Shao ZM; Di GH
Sci Rep; 2016 Aug; 6():32585. PubMed ID: 27576704
[TBL] [Abstract][Full Text] [Related]
4. A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer.
Jin X; Jiang YZ; Chen S; Yu KD; Ma D; Sun W; Shao ZM; Di GH
BMC Cancer; 2016 Aug; 16():606. PubMed ID: 27495967
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.
Jankowski C; Guiu S; Cortet M; Charon-Barra C; Desmoulins I; Lorgis V; Arnould L; Fumoleau P; Coudert B; Rouzier R; Coutant C; Reyal F
Breast Cancer Res Treat; 2017 Jan; 161(1):73-81. PubMed ID: 27807808
[TBL] [Abstract][Full Text] [Related]
6. A nomogram for predicting axillary pathologic complete response in hormone receptor-positive breast cancer with cytologically proven axillary lymph node metastases.
Guo R; Su Y; Si J; Xue J; Yang B; Zhang Q; Chi W; Chen J; Chi Y; Shao Z; Wu J
Cancer; 2020 Aug; 126 Suppl 16():3819-3829. PubMed ID: 32710664
[TBL] [Abstract][Full Text] [Related]
7. Validation of CTS5 Model in Large-scale Breast Cancer Population and Combination of CTS5 and Ki-67 Status to Develop a Novel Nomogram for Prognosis Prediction.
Ning L; Liu Y; He X; Han R; Xin Y; Zhao J; Liu X
Am J Clin Oncol; 2024 May; 47(5):228-238. PubMed ID: 38131531
[TBL] [Abstract][Full Text] [Related]
8. Nomogram for predicting preoperative regional lymph nodes metastasis in patients with metaplastic breast cancer: a SEER population-based study.
Zhang M; Wang B; Liu N; Wang H; Zhang J; Wu L; Zhao A; Wang L; Zhao X; Yang J
BMC Cancer; 2021 May; 21(1):565. PubMed ID: 34001061
[TBL] [Abstract][Full Text] [Related]
9. Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors.
Nakamura R; Yamamoto N; Shiina N; Miyaki T; Ikebe D; Itami M; Shida T; Miyazaki M
Breast; 2016 Apr; 26():141-7. PubMed ID: 26732051
[TBL] [Abstract][Full Text] [Related]
10. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
Robertson S; Rönnlund C; de Boniface J; Hartman J
Breast Cancer Res Treat; 2019 Apr; 174(3):795-805. PubMed ID: 30659433
[TBL] [Abstract][Full Text] [Related]
11. Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer.
Asogan AB; Hong GS; Arni Prabhakaran SK
Singapore Med J; 2017 Mar; 58(3):145-149. PubMed ID: 27029805
[TBL] [Abstract][Full Text] [Related]
12. Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
Fujii T; Kogawa T; Wu J; Sahin AA; Liu DD; Chavez-MacGregor M; Giordano SH; Raghavendra A; Murthy RK; Tripathy D; Shen Y; Yamal JM; Ueno NT
Br J Cancer; 2017 Feb; 116(4):509-514. PubMed ID: 28081544
[TBL] [Abstract][Full Text] [Related]
13. Laboratory indicators predict axillary nodal pathologic complete response after neoadjuvant therapy in breast cancer.
Chen P; Zhao T; Bi Z; Zhang ZP; Xie L; Liu YB; Song XG; Song XR; Wang CJ; Wang YS
Future Oncol; 2021 Jul; 17(19):2449-2460. PubMed ID: 33878939
[TBL] [Abstract][Full Text] [Related]
14. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis.
Chen X; Yuan Y; Gu Z; Shen K
Breast Cancer Res Treat; 2012 Aug; 134(3):957-67. PubMed ID: 22370627
[TBL] [Abstract][Full Text] [Related]
16. A validated web-based nomogram for predicting positive surgical margins following breast-conserving surgery as a preoperative tool for clinical decision-making.
Pleijhuis RG; Kwast AB; Jansen L; de Vries J; Lanting R; Bart J; Wiggers T; van Dam GM; Siesling S
Breast; 2013 Oct; 22(5):773-9. PubMed ID: 23462681
[TBL] [Abstract][Full Text] [Related]
17. A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age.
Yu J; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
J Transl Med; 2021 Feb; 19(1):75. PubMed ID: 33593381
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a clinicoradiomic nomogram to assess the HER2 status of patients with invasive ductal carcinoma.
Xu A; Chu X; Zhang S; Zheng J; Shi D; Lv S; Li F; Weng X
BMC Cancer; 2022 Aug; 22(1):872. PubMed ID: 35945526
[TBL] [Abstract][Full Text] [Related]
19. Validation over time of a nomogram including HER2 status to predict the sentinel node positivity in early breast carcinoma.
Ngô C; Mouttet D; De Rycke Y; Reyal F; Fourchotte V; Hugonnet F; Falcou MC; Bidard FC; Vincent-Salomon A; Fourquet A; Alran S
Eur J Surg Oncol; 2012 Dec; 38(12):1211-7. PubMed ID: 22954526
[TBL] [Abstract][Full Text] [Related]
20. Individualized model for predicting pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: A multicenter study.
Qian B; Yang J; Zhou J; Hu L; Zhang S; Ren M; Qu X
Front Endocrinol (Lausanne); 2022; 13():955250. PubMed ID: 36060977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
